荟萃分析:原发性硬化性胆管炎活体与 deceased 肝移植比较
该荟萃分析纳入22项研究、22024例患者,比较原发性硬化性胆管炎(PSC)活体肝移植(LDLT)与 deceased 供肝肝移植(DDLT)的结局。结果显示LDLT与更高的1、3、5年生存率相关,DDLT与更高的脓毒症、急性排斥和PSC复发风险相关,但胆道并发症风险更低。
要点
- LDLT组1、3、5年生存率均高于DDLT组。
- DDLT组脓毒症、急性排斥和PSC复发风险更高,胆道并发症风险更低。
- PSC需肝移植患者应考虑LDLT。
核心结论
- 在PSC患者中,LDLT似乎与比DDLT更高的移植后生存率相关。
- 该差异可能归因于更早转诊、更低的肝病负担、更好的体能状态、更好的移植物质量以及更短冷缺血时间。
研究设计与样本
- 系统综述与荟萃分析,检索PubMed、Web-of-Science、Scopus和Cochrane Central,从建库至2024年12月。
- 共纳入22项研究,纳入22024例患者。
主要发现
- 与LDLT相比,DDLT与更低的1年生存率相关(93.80% [95% CI 93.29-94.31] vs. 95.78% [95% CI 94.68-96.88])。
- 与LDLT相比,DDLT与更低的3年生存率相关(88.81% [95% CI 88.14-89.48] vs. 93.23% [95% CI 91.85-94.61])。
- 与LDLT相比,DDLT与更低的5年生存率相关(85.18% [95% CI 84.43-85.92] vs. 91.54% [95% CI 91.01-93.07]),但对移植物生存无影响。
- DDLT与更高的移植后脓毒症风险(OR 3.68 [95% CI 1.02-13.26])、急性排斥风险(OR 1.75 [95% CI 1.12-2.73])和PSC复发风险(OR 1.63 [95% CI 1.10-2.42])相关,但胆道并发症风险更低(OR 0.29 [95% CI 0.11-0.78])。
- DDLT受者年龄更大(MD 4.26岁 [95% CI 2.42-6.10]),代谢功能障碍更重,肝病更晚期(MELD更高:MD 6.63 [95% CI 5.56-7.70]),但合并炎症性肠病(OR 0.66 [95% CI 0.50-0.87])或胆管癌(OR 0.70 [95% CI 0.53-0.92])的机会更低;DDLT供者年龄更大(MD 2.46岁 [95% CI 0.76-4.15]),冷缺血时间更长(MD 5.63小时 [95% CI 3.18-8.08])。
临床怎么用
- 对于需要肝移植的PSC患者,应鼓励其考虑活体肝移植(LDLT)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Primary sclerosing cholangitis (PSC) is a rare disease that paradoxically accounts for 5%-15% of liver transplants (LT). The paucity of liver donors is boosting living donor LT (LDLT). We reviewed the literature regarding outcomes of LT in PSC, comparing LDLT with deceased donor LT (DDLT). METHODS: A systematic review with meta-analysis was performed through a search on: PubMed, Web-of-Science, Scopus and Cochrane Central, from inception to December 2024. In total, 22 studies were included, enrolling 22,024 patients. RESULTS: Compared with LDLT, DDLT was associated with lower 1- (93.80% [95% CI 93.29-94.31] vs. 95.78% [95% CI 94.68-96.88]), 3- (88.81% [95% CI 88.14-89.48] vs. 93.23% [95% CI 91.85-94.61]) and 5-year survival (85.18% [95% CI 84.43-85.92] vs. 91.54% [95% CI 91.01-93.07]), although it had no impact on graft survival. DDLT was associated with a higher risk of post-LT sepsis (OR 3.68 [95% CI 1.02-13.26]), acute rejection (OR 1.75 [95% CI 1.12-2.73]) and PSC recurrence (OR 1.63 [95% CI 1.10-2.42]), but a lower risk of biliary complications (OR 0.29 [95% CI 0.11-0.78]). DDLT recipients were older (MD 4.26 years [95% CI 2.42-6.10]), with higher metabolic dysfunction, more advanced liver disease (higher MELD: MD 6.63 [95% CI 5.56-7.70]), but lower chances of having inflammatory bowel disease (OR 0.66 [95% CI 0.50-0.87]) or cholangiocarcinoma (OR 0.70 [95% CI 0.53-0.92]). DDLT donors were older (MD 2.46 years [95% CI 0.76-4.15]) and cold ischemia time was longer (MD 5.63 h [95% CI 3.18-8.08]). CONCLUSION: In PSC, LDLT seems to be associated with higher post-LT survival, compared with DDLT. This could be explained by earlier referral to LT with lower liver disease burden and better performance status; better graft quality; and shorter cold ischaemia time. PSC patients requiring LT should be encouraged to consider LDLT.
引用
- Afonso AB, da Silva CM, Nogueira P, et al. Meta-Analysis: Comparison of Living Versus Deceased Liver Transplantation for Primary Sclerosing Cholangitis. Aliment Pharmacol Ther. 2025. PMID: 40890931. doi:10.1111/apt.70357
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。